You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Renal cancer

Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

  • Technology appraisal guidance
  • Reference number: TA333
  • Published:  25 February 2015
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Renal cell carcinoma (advanced) - axitinib: consultee and commentator comments on the ACD

  • Renal cell carcinoma (advanced) - axitinib: Pfizer

  • Renal cell carcinoma (advanced) - axitinib: Commissioning Support Appraisal Service

  • Renal cell carcinoma (advanced) - axitinib: James Whale Fund for Kidney Cancer

  • Renal cell carcinoma (advanced) - axitinib: Kidney Cancer UK


This page was last updated: 25 March 2013

Back to top